Business Wire

Bryn Pharma’s UTULY™ 13.2mg Intranasal Epinephrine Spray Provides Higher and More Sustained PK Compared to Standard Reference Product, the 0.3mg Epinephrine Autoinjector ...

RALEIGH, N.C.--(BUSINESS WIRE)--Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat ...
Business Insider

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine ...

Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection Data ...
Nasdaq

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems ...
Mena FN

Bryn Pharma Announces First Participant Dosed In PK/PD Trial With Upgraded Nasal Spray Device, Including First-Of-Its-Kind, Two-Doses-In-One Nasal Spray Profile

New clinical trial data with Bryn Pharma's second-generation epinephrine nasal spray expected in Q3 2025 The trial employs an upgraded two-spray nasal spray device providing additional reliability and ...